The first generation of SARS-CoV2 monoclonals (and combinations) have lost their utility.
Red is bad, green is good. After all that struggle to get these to the market, the virus has evaded them.
"individuals who are immunocompromised (eg, because of comorbidities, high age, or immunosuppressive treatment) might not mount a full adaptive immune response and thus remain susceptible. For individuals at high risk, individual monoclonal antibodies (mAbs) or cocktails of mAbs are administered as prophylaxis or therapy."
"Our data reveal that emerging omicron sublineages are resistant to most (ie, BA.4.6, BA.2.75.2, and BJ.1) or all (BQ.1.1) clinically used mAbs. As a consequence, in patients at high risk, treatment with mAbs alone might not provide a therapeutic benefit in regions of the globe in which BQ.1.1 is spreading, suggesting that additional treatment options (eg, paxlovid or molnupiravir) should be considered. Furthermore, novel, broadly active mAbs are urgently needed for prophylactic or therapeutic treatment, or both, in patients at high risk."
Assistant Professor at Georgetown University
2 年Are the manufacturers of SARS-CoV2 mAbs willing to tolerate such a short period of profitability to justify the next generation of mAbs for the elderly?